Skip to content

Study · Measured the body's own peptide · 2012

4 results

Association between serum thymosin β4 levels of rheumatoid arthritis patients and disease activity and response to therapy.

Song R, Choi HM, Yang HI, Yoo MC, Park YB, Kim KS

Clinical rheumatology1 Jun 2012Cited by 7 (Europe PMC)

PMID22653616 (opens in a new tab)DOI10.1007/s10067-012-2011-7 (opens in a new tab)PepBankPUB-22653616
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Natural levels measured4

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In patients with rheumatoid arthritis, serum Tβ4 levels were positively and significantly associated with disease activity by the 28-joint Disease Activity Score.

    In plain wordsIn people with rheumatoid arthritis, higher natural thymosin β4 levels were linked to higher disease activity.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseAssociation of Tβ4 with DAS28 disease activity
    Study

    n = 40

    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    Tβ4 levels were significantly associated with disease activity according to the 28-joint Disease Activity Score.
    3 context sentences
    Summary · context
    Tβ4 levels were increased in the serum of patients with RA and were positively associated with disease activity.
    Summary · context
    Blood samples from 40 patients with RA were collected at baseline and 6 months after starting treatment with disease-modifying antirheumatic drugs (DMARD) and/or tumor necrosis factor (TNF)-α blocker.
    Summary · context
    Serum levels of Tβ4 were measured by ELISA.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    In patients with rheumatoid arthritis, serum Tβ4 levels were about tenfold higher than in healthy controls.

    In plain wordsIn people with rheumatoid arthritis, the body's own thymosin β4 in blood was about ten times higher than in healthy people.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseSerum Tβ4 in RA patients versus healthy controls
    Study

    n: not reported in source

    Comparator
    Healthy controls
    Outcome group
    Inflammation markers · Immune and inflammation

    Measurements

    Serum Tβ4
    577.4 ng/mL
    RA patients
    Serum Tβ4
    56.61 ng/mL
    healthy controls

    Source sentences

    Summary
    Tβ4 levels (mean ± standard deviation) in RA patients were significantly (approximately tenfold) higher than in healthy controls (577.4 ± 67.92 vs. 56.61 ± 5.72 ng/mL).
    2 context sentences
    Summary · context
    Blood samples from 40 patients with RA were collected at baseline and 6 months after starting treatment with disease-modifying antirheumatic drugs (DMARD) and/or tumor necrosis factor (TNF)-α blocker.
    Summary · context
    Serum levels of Tβ4 were measured by ELISA.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelObservational studyOther

    In patients with rheumatoid arthritis, serum Tβ4 before therapy was slightly higher in severe than in moderate disease activity, without a significant difference (P > 0.05).

    In plain wordsIn people with rheumatoid arthritis, the body's own thymosin β4 was slightly higher with severe disease than with moderate disease, but not significantly.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    No significant changeSerum Tβ4 by disease activity (severe vs moderate)
    Study

    n: not reported in source

    Comparator
    Moderate disease activity
    Outcome group
    Inflammation markers · Immune and inflammation

    Measurements

    Serum Tβ4
    662.4 ng/mL
    severe disease activity
    Serum Tβ4
    462.5 ng/mL
    moderate disease activity

    Source sentences

    Summary
    Serum Tβ4 levels in patients with severe disease activity before therapy were slightly higher than in patients with moderate disease activity (662.4 ± 491.5 vs. 462.5 ± 305.3 ng/ml, P > 0.05).
    2 context sentences
    Summary · context
    Blood samples from 40 patients with RA were collected at baseline and 6 months after starting treatment with disease-modifying antirheumatic drugs (DMARD) and/or tumor necrosis factor (TNF)-α blocker.
    Summary · context
    Serum levels of Tβ4 were measured by ELISA.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  4. 04HumanEndogenous levelObservational studyOther

    In patients with rheumatoid arthritis, mean baseline Tβ4 was significantly lower in the DMARD group than in the DMARD + TNF-α blocker group.

    In plain wordsIn people with rheumatoid arthritis, natural thymosin β4 at baseline was lower in the group on one drug type than in the group on two.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseBaseline Tβ4 by treatment group (DMARD vs DMARD + TNF-α blocker)
    Study

    n: not reported in source

    Comparator
    DMARD + TNF-α blocker group
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    The mean Tβ4 level at baseline in the DMARD treatment group was significantly lower than in the DMARD + TNF-α blocker treatment group.
    2 context sentences
    Summary · context
    Blood samples from 40 patients with RA were collected at baseline and 6 months after starting treatment with disease-modifying antirheumatic drugs (DMARD) and/or tumor necrosis factor (TNF)-α blocker.
    Summary · context
    Serum levels of Tβ4 were measured by ELISA.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.